how much is microdosing tirzepatide with Mounjaro KwikPens | Scott Isaacs, MD, FACP, FACE posted on the topic Microdosing tirzepatide chart: Guide to

Stay consistent to avoid weight cycling: Repeated cycles of weight loss and regain can lead to cumulative muscle loss and reduced strength over time

Suitable candidates include: Patients with type 2 diabetes and a BMI of 35 kg/m or higher (or 32.5 kg/m or higher for people of South Asian or other minority ethnic backgrounds), or where weight loss would benefit other significant obesity-related comorbidities Those with type 2 diabetes who have not achieved target HbA1c levels with metformin and other oral medications People for whom weight loss would benefit other obesity-related comorbidities or where weight-neutral treatment options are preferred Individuals with occupational implications where insulin therapy would be problematic Importantly, NICE recommends continuing GLP-1 receptor agonist treatment only if there is a beneficial metabolic response: after 6 months, treatment should continue only if HbA1c has decreased by at least 11 mmol/mol (1.0%) and weight has decreased by at least 3% from initial body weight

Read the full paper in Diabetes Research & Clinical Practice: Figure: intestinal secretion of GLP-1 & #GIP Research by Professor Naila Rabbani & Paul Thornalley

High-fat and fried foods are primary culprits for nausea and delayed gastric emptying

124 Therefore, it was speculated that peptide drugs are unlikely to be involved in the occurrence of transporter-mediated DDIs